Clinical trials
catalyst calendar across sponsors →Studies where NUE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 observational
Held by 19 tracked-famous managers (Berkshire Hathaway Inc, Qube Research & Technologies Ltd, TWO SIGMA INVESTMENTS, LP, JANE STREET GROUP, LLC, Bridgewater Associates, LP, +14 more) · FINRA short interest 2.5 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 4 sells · government filings 180d: 0 congress / 1 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Comprehensive Optical Blood Pressure Assessment Tool to Identify Cases of Unscreened Hypertension Across an Active Population in the U.S.NCT06721611observationalThe percentage of subjects with undiagnosed hypertension | — | Withdrawnsponsor's stated reason: The study was aborted by the sponsor. | Device: Optical Blood Pressure Monitoring Device (Aktiia G1) | Hypertension | 0 | 2025-07-16 | 2025-02-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19